Recent Updates
Recently added Catalysts
TTRX Positive Sentiment

Turn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Turn Therapeutics announced that its therapy GX-03 received the 'Developmental Immunology Solution of the Year' award in the 2026 BioTech Breakthrough Awards. This recognition reflects the company's commitment to developing targeted therapies for inflammatory skin diseases. The award was presented by BioTech Breakthrough, a respected market intelligence organization.

Market Sentiment Analysis

POSITIVE FACTORS

  • GX-03 recognized for its innovative approach.
  • Award highlights Turn Therapeutics' achievements.
  • Recognition from a reputable independent organization.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~31 mo
Minimal dilution risk
Lead asset
GX-03
Phase 2 · Eczema Atopic Dermatitis

Full Press Release Details

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that GX-03 has been selected as “Developmental Immunology Solution of the Year” in the sixth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and bio

Frequently Asked Questions

What award did GX-03 receive?

GX-03 was awarded 'Developmental Immunology Solution of the Year'.

Who presented the award to GX-03?

The award was presented by BioTech Breakthrough.

What is the focus of Turn Therapeutics?

Turn Therapeutics develops therapies for inflammatory skin diseases.

When was the award announced?

The award announcement was made in 2026.

ShareAdd on Google
Tags: TTRX Turn Therapeutics GX-03 BioTech Breakthrough Awards immunology
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$10M liquidity · $0M/mo burn
~31 mo
Minimal dilution risk
Lead asset
GX-03Phase 2
Eczema Atopic Dermatitis →